Drug Profile
Anti-PSMA CAR NK cell therapy - Allife Medical Science and Technology
Alternative Names: Anti-PSMA CAR NK cells - Allife Medical Science and TechnologyLatest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Allife Medical Science and Technology
- Class CAR-NK cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Prostate-cancer in Unknown (Parenteral, Injection)
- 04 Oct 2018 Allife Medical Science and Technology plans a phase I trial for Prostate cancer (In adults, In the elderly, Metastatic disease, Second-line therapy or greater) in December 2018 (NCT03692663)
- 01 Apr 2018 Preclinical trials in Prostate cancer (Parenteral)